The Cooper Companies, Inc. Earnings Recaps
Investors reacted sharply negatively, with the stock falling 20%, as CooperVision’s U.S. channel inventory reduction drove essentially flat quarterly revenue and is expected to weigh on Q4. The strategic review also ended without a sale of CooperSurgical, leaving the company to pursue a longer-term value-creation plan amid weaker near-term contact-lens performance.
Key takeaways
- CooperVision revenue was **$717 million, essentially flat year over year**; U.S. channel inventory reductions were the primary drag, while EMEA and Asia Pacific were broadly in line with expectations.
- Management said the inventory reduction will **continue to impact Q4**, despite reporting mid-single-digit U.S. consumption growth and positioning the channel for fiscal 2027.
- Product momentum was mixed: the **MyDay franchise delivered double-digit growth** in several categories and regions, while clariti was softer outside EMEA and Biofinity was flat after U.S. inventory actions.
- CooperSurgical remains part of the company after the Board rejected potential sale proposals, citing temporary valuation pressures tied to a non-hormonal IUD competitor and fertility litigation settlement.
- Positives included **record free cash flow**, solid fertility growth at CooperSurgical, and a favorable resolution of a significant tax matter; management also plans increased commercial investment and potential share repurchases.
Cooper Companies reported a strong Q1 2026, driven by robust sales growth in its CooperVision segment and significant operational efficiencies, resulting in heightened earnings and free cash flow.
Key takeaways
- Consolidated revenues reached $1.024 billion, reflecting a 6.2% year-over-year increase, with CooperVision achieving 7.6% growth.
- Non-GAAP earnings per share rose 20% to $1.10, exceeding guidance expectations.
- Free cash flow totaled $159 million, allowing for increased guidance on both earnings and cash flow for the year.
- Product launches, particularly within the MyDay portfolio, contributed significantly to market share gains, especially in the Americas and EMEA regions.
- The strategic review process is ongoing, focused on maximizing long-term shareholder value amidst strong operational momentum.
Cooper Companies reported a strong Q4 2025 with revenues reaching $1.065 billion, marking an organic growth of 3.4%. The company continues to demonstrate robust earnings growth and commitment to shareholder returns through substantial stock repurchases.
Key takeaways
- Q4 revenues increased 4.6% year-over-year, with CooperVision revenues of $710 million, driven by improved MyDay availability despite some market softness in China.
- Non-GAAP earnings grew 11% to $1.15, achieving the eighth consecutive quarter of beating consensus expectations.
- Free cash flow for Q4 totaled $150 million, contributing to an updated target of over $2.2 billion for fiscal 2026-2028.
- Nearly $200 million of stock was repurchased in Q4, with plans to allocate a similar percentage of free cash flow to share buybacks in fiscal 2026.
- A formal strategic review has been initiated to explore long-term shareholder value opportunities, alongside enhancements to executive performance metrics linked to total shareholder return.